ASMB - Assembly Biosciences to Present New Data at AASLD The Liver Meeting® | Benzinga
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company's interferon-? receptor agonist program --
SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.
At the meeting, one poster presentation will share new preclinical data from the Company's interferon-? receptor (IFNAR) agonist program in chronic hepatitis B virus (HBV), currently in lead optimization. Additionally, an oral presentation will highlight data from the Phase 2 study of first-generation core inhibitor vebicorvir (VBR) in combination with nucleos(t)ide reverse transcriptase inhibitor (Nrtl) and Arbutus Biopharma's AB-729 in virologically suppressed patients with hepatitis B e antigen negative chronic HBV.
"We look forward to presenting data at this year's AASLD, The Liver Meeting®, featuring the exciting progress of our preclinical IFNAR agonist program and its potential to engage the interferon-? pathway with improved tolerability through an oral, liver-focused approach," said William Delaney, PhD, chief scientific officer of Assembly Bio. "Additionally, we're pleased to share further insights from the Phase 2 data reported for vebicorvir in combination with Nrtl and Arbutus Biopharma's AB-729 with the HBV and liver disease scientific community."
Details of the poster ...